Trial Profile

A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Feb 2021 According to a Glaukos Corporation media release, this Phase 3 trial results are expected to support the U.S. NDA submission in 2022 and the company is targeting U.S. FDA approval for Epi-on in 2023.
25 Feb 2021 Primary endpoint (Improvement in maximum corneal curvature (Kmax) at 6 months from baseline between the treated and placebo-controlled arms) has been met, according to a Glaukos Corporation media release.
25 Feb 2021 Results presented in a Glaukos Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com